Literature DB >> 36255639

Cloning Strategy for HDAC1/HDAC2 Hybrid Protein Expression in Mammalian Cells.

Désirée Gül1, Sandra Olf2, Jan Hagemann2, Roland H Stauber2, Oliver H Krämer3.   

Abstract

Dynamic deacetylation of non-histone proteins by histone deacetylases (HDACs) is a key regulator of protein functions, interactions, and turnover. Among class I HDACs, human HDAC1 and HDAC2 share more than 80% global homology at the amino acid level. However, despite the high redundancy, there are examples for differential substrate specificities of HDAC1 and HDAC2. Until now it remains quite unclear how specific and overlapping functions of HDAC1/HDAC2 are regulated in different contexts. Here, we describe molecular cloning techniques for the generation of HDAC1/HDAC2 hybrid proteins, HDAC1/HDAC2 mutants lacking known interaction domains, and HDAC1/HDAC2 hybrid proteins with interchanged N-terminal domains. These proteins are tools for the analysis of specific protein interactions and functions in mammalian cells.
© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Domain analysis; HDAC1; HDAC2; Hybrid protein; Molecular cloning

Mesh:

Substances:

Year:  2023        PMID: 36255639     DOI: 10.1007/978-1-0716-2788-4_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  Distinct and redundant functions of histone deacetylases HDAC1 and HDAC2 in proliferation and tumorigenesis.

Authors:  Jennifer Jurkin; Gordin Zupkovitz; Sabine Lagger; Reinhard Grausenburger; Astrid Hagelkruys; Lukas Kenner; Christian Seiser
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

2.  The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.

Authors:  Nicole Kiweler; Boris Brill; Matthias Wirth; Ines Breuksch; Teresa Laguna; Cornelia Dietrich; Susanne Strand; Günter Schneider; Bernd Groner; Falk Butter; Thorsten Heinzel; Walburgis Brenner; Oliver H Krämer
Journal:  Arch Toxicol       Date:  2018-05-29       Impact factor: 5.153

3.  Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients.

Authors:  Michela Tassara; Konstanze Döhner; Peter Brossart; Gerhard Held; Katharina Götze; Heinz-A Horst; Mark Ringhoffer; Claus-Henning Köhne; Stephan Kremers; Aruna Raghavachar; Gerald Wulf; Heinz Kirchen; David Nachbaur; Hans Günter Derigs; Mohammed Wattad; Elisabeth Koller; Wolfram Brugger; Axel Matzdorff; Richard Greil; Gerhard Heil; Peter Paschka; Verena I Gaidzik; Martin Göttlicher; Hartmut Döhner; Richard F Schlenk
Journal:  Blood       Date:  2014-05-05       Impact factor: 22.113

4.  HDAC2 Facilitates Pancreatic Cancer Metastasis.

Authors:  Lukas Krauß; Bettina C Urban; Sieglinde Hastreiter; Carolin Schneider; Patrick Wenzel; Zonera Hassan; Matthias Wirth; Katharina Lankes; Andrea Terrasi; Christine Klement; Filippo M Cernilogar; Rupert Öllinger; Niklas de Andrade Krätzig; Thomas Engleitner; Roland M Schmid; Katja Steiger; Roland Rad; Oliver H Krämer; Maximilian Reichert; Gunnar Schotta; Dieter Saur; Günter Schneider
Journal:  Cancer Res       Date:  2022-02-15       Impact factor: 12.701

5.  HDAC1 and HDAC2 integrate checkpoint kinase phosphorylation and cell fate through the phosphatase-2A subunit PR130.

Authors:  Anja Göder; Claudia Emmerich; Teodora Nikolova; Nicole Kiweler; Maria Schreiber; Toni Kühl; Diana Imhof; Markus Christmann; Thorsten Heinzel; Günter Schneider; Oliver H Krämer
Journal:  Nat Commun       Date:  2018-02-22       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.